Incyte Corporation vs Prudential Financial Inc — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Prudential Financial Inc trades at $117.2 (market cap $40.97B). The key difference: Prudential Financial Inc is the larger of the two by market cap, and Prudential Financial Inc pays a 4.75% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PRU | |
|---|---|---|
Market Cap | $23.11B | $40.97B |
Sector | Health | Financials |
52-Week High | $118.52 | $119.07 |
52-Week Low | $67.38 | $92.00 |
Enterprise Value | $19.13B | $68.03B |
Dividend Yield | — | 4.75% |
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Prudential Financial (PRU) trades at $118.59, down 0.4% with mixed technical signals showing bullish moving averages but neutral oscillators. The company demonstrates solid fundamentals with a P/E of 12.15, net income margin of 5.5%, and consistent earnings beats in recent quarters. Recent business developments include expanding retirement offerings and international growth initiatives, supported by strong cash flow generation of $6.27B from operations in 2025.
PRU presents a compelling value opportunity with attractive valuation metrics and steady profitability, though analyst sentiment remains cautious with 68% hold ratings. Key risks include significant investing outflows and debt levels, while catalysts include upcoming Q2 earnings and continued retirement market expansion. The stock trades above consensus price targets, suggesting limited near-term upside potential despite fundamental strength.
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →